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Background
DNA and rAd5 vaccines delivered intramuscularly have
been studied in many phase I/II trials. Here, the immuno-
genicity of the NIAID Vaccine Research Center (VRC)
DNA and rAd5 HIV-1 vaccines were evaluated after injec-
tion by intramuscular (IM), subcutaneous (SC) and intra-
dermal (ID) routes of administration.
Methods
60 subjects were randomized to one of two schedules.
Group 1 received 3 DNA vaccine injections followed by a
recombinant adenoviral vector (rAd5) vaccine booster;
Group 2 received rAd5 prime followed by rAd5 booster.
Within each Group subjects were equally randomized to
prime injections by the IM, SC or ID routes of administra-
tion and all groups received a boost with rAd5 by IM injec-
tion. Half of the subjects in each group had pre-existing
Ad5 neutralizing antibody.
Results
All routes induced T cell and humoral immune responses
in Ad5 naïve and pre-immune subjects. >95% of subjects
made an antibody response to Env. T cell responses to Env
were seen in >80% and T cell responses to Gag were seen
in >50% of all study subjects. Env T cell responses were of
greater magnitude than responses to Gag. The frequency
and magnitude of T cell responses were not diminished in
Ad5 pre-immune subjects as compared to naïve subjects
in either of the ID primed groups.
Conclusion
In this exploratory study, SC delivery of DNA or rAd5 as a
prime does not induce a higher frequency or magnitude of
T cell immunity than IM delivery. ID delivery may provide
a dose sparing effect and also deserves additional evalua-
tion as a means to overcome pre-existing vector immu-
nity.
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